ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Calcineurin"

  • 2022 American Transplant Congress

    Tacrolimus Induces Dedifferentiation of Pancreatic Beta Cells by Inhibition of Calcineurin/NFATc2 and Islet Cell Differentiation Genes

    C. M. Darden1, S. Vasu2, J. Mattke3, Y. Liu2, B. Naziruddin4, M. C. Lawrence2

    1Baylor University, Dallas, TX, 2Baylor University Medical Center, Dallas, TX, 3Baylor University, Waco, TX, 4Baylor University Medical Ctr, Dallas, TX

    *Purpose: Tacrolimus (FK506) is a potent immunosuppressant widely used for solid organ transplantation to prevent lymphokine gene expression by inhibiting calcineurin (CN) and its downstream…
  • 2022 American Transplant Congress

    Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient

    H. Sasaki, H. Harada, D. Takamoto, Y. Takada, S. Harada, H. Tanaka

    Sapporo City General Hospital, Sapporo, Japan

    *Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…
  • 2022 American Transplant Congress

    Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy

    T. Engebretsen1, M. Kueht1, A. Lea2, M. Mujtaba3

    1Abdominal Transplant Surgery, University of Texas Medical Branch, Galveston, TX, 2Infectious Disease, University of Texas Medical Branch, Galveston, TX, 3Nephrology, University of Texas Medical Branch, Galveston, TX

    *Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…
  • 2022 American Transplant Congress

    Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption

    M. Chandran1, D. Yoeli1, A. Sater2, F. Karrer1, M. Adams1

    1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO

    *Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…
  • 2022 American Transplant Congress

    Impact of Biliary Reconstruction on Tacrolimus Absorption in Pediatric Liver Transplant

    M. Chandran1, D. Yoeli1, A. Sater2, M. Adams1, F. Karrer1

    1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO

    *Purpose: Tacrolimus (FK506) oral bioavailability in pediatric liver transplant recipients (LTR) is poor. Enteral FK506 is primarily absorbed in the small intestine and subject to…
  • 2022 American Transplant Congress

    Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients

    Y. Chen1, J. Ahn1, N. Chu1, S. Bae1, M. A. Schnitzler2, G. Hess3, K. Lentine4, D. Segev5, M. McAdams-DeMarco1

    1Johns Hopkins School of Medicine, Baltimore, MD, 2Surgery, Saint Louis University, O Fallon, IL, 3Drexel University School of Medicine, Philadelphia, PA, 4Saint Louis University, St. Louis, MO, 5Johns Hopkins University, Baltimore, MD

    *Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…
  • 2021 American Transplant Congress

    Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients

    J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange

    NewYork-Presbyterian Hospital, New York, NY

    *Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
  • 2021 American Transplant Congress

    Relationship Between Tacrolimus Blood Levels and Covid-19 Pandemic in Kidney Transplant Recipients

    T. Inoue1, K. Unagami,2, A. Ishiwatari3, T. Kanzawa3, T. Shimizu3, K. Omoto3, M. Inui3, T. Suzuki1, H. Ishida4, K. Tanabe3

    1Department of Nephrology, Kameda Medical Center, Chiba Kamogawa, Japan, 2Department of Organ Transplant Medicine, Tokyo Women’s Medical University, Tokyo, Japan, 3Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, 4Department of Organ transplant medicine, Tokyo Women’s Medical University, Tokyo, Japan

    *Purpose: The novel coronavirus 2019 infection (COVID-19) caused a pandemic, prompting Tokyo, Japan, to restrict on the free movement of people in March 2020. Kidney…
  • 2021 American Transplant Congress

    A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression

    E. Huang, A. Vo, A. Peng, R. Najjar, S. Sethi, S. Jordan

    Cedars-Sinai Medical Center, Los Angeles, CA

    *Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…
  • 2021 American Transplant Congress

    Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II

    M. Béland, S. De Serres

    Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada

    *Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences